SAN DIEGO, March 13, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused platform technologycompany that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that Carmine N. Stengone, President and Chief Executive Officer, will present at the
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
View original content:http://www.prnewswire.com/news-releases/avelas-biosciences-to-present-at-oppenheimer-28th-annual-healthcare-conference-300613403.html
SOURCE Avelas Biosciences, Inc.
Subscribe to our Free Newsletters!